Compass Pathways stock rallies as Trump’s new executive order aims at accelerating approval and research of psychedelic ...

Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.

Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS Pathways plc (NASDAQ:CMPS) is given fourth position on our list of most promising ...

A synthetic form of psilocybin, the active compound in magic mushrooms, has delivered strong results during late-stage ...

Trump signed an order to accelerate the regulatory progression of psychedelic therapies. Can Compass Pathways make use of it?

Ever since psychedelic medicine in the U.S. was stymied by government action, the field has been steadily clawing its way ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House ...

Last weekend, President Donald Trump signed an executive order aimed at accelerating the review of psychedelic therapies for mental health conditions. At a high level, the order does three things. It ...